Long acting injectable aripiprazole for bipolar one patients has been shown to significantly reduce the risk of a recurrence of a mood episode in a 52 week placebo controlled clinical trial. Poor adherence to treatment is a significant problem in patients with bipolar disorder, putting patients at increased risk of recurrence of mood episodes, hospitalization, and suicide. One other study …